- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.
Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-Mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studienorte
-
-
Quebec
-
Chicoutimi, Quebec, Kanada
- Rekrutierung
- Site CA01194
-
Montreal, Quebec, Kanada
- Rekrutierung
- Site CA01071
-
Montreal, Quebec, Kanada
- Rekrutierung
- Site CA01052
-
-
-
-
-
Daegu, Südkorea
- Rekrutierung
- Site KR01113
-
Seongnam-si, Südkorea
- Rekrutierung
- Site KR01063
-
Seoul, Südkorea
- Rekrutierung
- Site KR01065
-
Seoul, Südkorea
- Rekrutierung
- Site KR01084
-
-
-
-
-
Kaohsiung City, Taiwan
- Rekrutierung
- Site TW01117
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72211
- Rekrutierung
- Arkansas Urology
-
-
California
-
Santa Barbara, California, Vereinigte Staaten, 93105
- Rekrutierung
- Samsun Clinic - Ridley-Tree Cancer Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rekrutierung
- Rocky Mountain Cancer Center
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Rekrutierung
- Medical Oncology Hematology Consultants
-
-
Illinois
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Rekrutierung
- Hope and Healing Clinical Research LLC
-
New Lenox, Illinois, Vereinigte Staaten, 60451
- Rekrutierung
- Hope and Healing Clinical Research LLC
-
Niles, Illinois, Vereinigte Staaten, 60714
- Rekrutierung
- Illinois Cancer Specialists
-
-
Indiana
-
Fort Wayne, Indiana, Vereinigte Staaten, 46825
- Rekrutierung
- Fort Wayne Medical Oncology and Hematology
-
-
Michigan
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Comprehensive Urology
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65201
- Rekrutierung
- Missouri Cancer Associates
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Siteman Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89106
- Rekrutierung
- Comprehensive Cancer Centers of Nevada - Southwest
-
-
New York
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Fairfield, Ohio, Vereinigte Staaten, 45014
- Rekrutierung
- Oncology Hematology Care Clinical Trials, LLC
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Rekrutierung
- Williamette Valley Cancer Institute and Research Center
-
Tigard, Oregon, Vereinigte Staaten, 97223
- Rekrutierung
- Compass Oncology - West
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78705
- Rekrutierung
- Texas Oncology
-
Tyler, Texas, Vereinigte Staaten, 75702
- Rekrutierung
- Texas Oncology - Northeast Texas
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22903
- Rekrutierung
- University of Virginia Comprehensive Cancer Center
-
Norfolk, Virginia, Vereinigte Staaten, 23502
- Rekrutierung
- Virginia Oncology Associates
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
- Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
- Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
- Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria:
- Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
- Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
- Prior pelvic radiation for any reason
- Inadequate bladder function
- Other active malignancies within 3 years prior to randomization
- Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
- Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
- Uncontrolled diabetes
- Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
- Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
- Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
- Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
- Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
- Active keratitis or corneal ulcerations
- History of autoimmune disease that has required systemic treatment in the past 2 years
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Prior allogeneic stem cell or solid organ transplant
- Received a live attenuated vaccine within 30 days prior to randomization
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A
Enfortumab vedotin + pembrolizumab (EV + P) |
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.
Andere Namen:
IV infusion on Day 1 of every 3-week cycle up to cycle 17.
Andere Namen:
|
|
Aktiver Komparator: Arm B
Concurrent Chemoradiotherapy (cCRT) |
64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes. 55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only. 40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation. 500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.
Andere Namen:
12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.
Andere Namen:
100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Zeitfenster: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Overall Survival (OS)
Zeitfenster: Up to approximately 60 months
|
Time from randomization to death due to any cause. |
Up to approximately 60 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Zeitfenster: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Zeitfenster: Up to approximately 60 months
|
cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology. |
Up to approximately 60 months
|
|
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Zeitfenster: Up to approximately 60 months]
|
Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first. |
Up to approximately 60 months]
|
|
Time to Cystectomy
Zeitfenster: Up to approximately 60 months
|
The time from randomization to cystectomy. |
Up to approximately 60 months
|
|
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Zeitfenster: Up to approximately 60 months
|
The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Cystectomy Free Survival (CFS)
Zeitfenster: Up to approximately 60 months
|
The time from randomization to cystectomy or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Zeitfenster: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
|
Number of Participants with Serious TEAEs
Zeitfenster: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienleiter: Zejing Wang, MD/PhD, Pfizer
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Gemcitabin
- Neubildungen
- Neoplasien der Harnblase
- Urothelkarzinom
- Cisplatin
- Pembrolizumab
- Fluorouracil
- Komplikationen
- Urologische Erkrankungen
- Urothelkrebs
- Enfortumab Vedotin
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Urologische Neubildungen
- Weibliche Urogenitalerkrankungen
- Männliche Urogenitalerkrankungen
- Muskelinvasiver Blasenkrebs
- Mitomycin
- Erkrankungen der Harnblase
- Blasenerhaltung
- Urogenitalerkrankungen
- Female Urogenital Diseases and Pregnancy
- Bladder-sparing
Zusätzliche relevante MeSH-Bedingungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Karzinom
- Urogenitale Erkrankungen
- Neubildungen
- Urologische Erkrankungen
- Neoplasien der Harnblase
- Urologische Neubildungen
- Karzinom, Übergangszelle
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Männliche Urogenitalerkrankungen
- Erkrankungen der Harnblase
- Weibliche Urogenitalerkrankungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Therapeutika
- Indolen
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Uracil
- Pyrimidinone
- Platinverbindungen
- Strahlentherapie
- Quinonen
- Azirinen
- Dosisfraktionierung, Strahlung
- Strahlentherapie -Dosierung
- Mitomycins
- Indolequinone
- Gemcitabin
- Fluoruracil
- Cisplatin
- Mitomycin
- Pembrolizumab
- Enfortumab Vedotin
- Hypofraktionierung der Strahlendosis
Andere Studien-ID-Nummern
- C5701009
- EV-309 (Andere Kennung: Alias Study Number)
- 2026-525612-34-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .